投资工具 / 美股
Vertex Pharmaceuticals · VRTX
数据仅供参考,不构成投资建议。
投资工具 / 美股
数据仅供参考,不构成投资建议。
| 季度 | 截止日 | 申报日 | 营收 | 营收同比 g | Δg | 推导方式 |
|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 2026-11-03 | $3.44B | +11.8% | −0.6pp | 3M |
| 2026Q2 | 2026-06-30 | 2026-08-04 | $3.33B | +12.5% | +4.6pp | 3M |
| 2026Q1 | 2026-03-31 | 2026-05-05 | $2.99B | +7.8% | −1.7pp | 3M |
| 2025Q4 | 2025-12-31 | 2026-11-03 | $3.19B | +9.5% | −1.4pp | FY-9M |
| 2025Q3 | 2025-09-30 | 2026-11-03 | $3.08B | +11.0% | −1.1pp | 3M |
| 2025Q2 | 2025-06-30 | 2026-08-04 | $2.96B | +12.1% | +9.1pp | 3M |
| 2025Q1 | 2025-03-31 | 2026-05-05 | $2.77B | +3.0% | −12.7pp | 3M |
| 2024Q4 | 2024-12-31 | 2026-02-13 | $2.91B | +15.7% | +4.0pp | FY-9M |
口径:单季同比;Δg = 本季 g − 上季 g;按财季映射日历季度;申报日可见。† 不连续点(上年同季营收 ≤0 或 Δg 幅度超过 50pp)。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 季度 | 截止日 | 毛利 | 销货成本 | 毛利率 | 环比 | 同比 | Δ² |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 无数据 | $526.1M | 84.7% | −62bp | −181bp | −88bp |
| 2026Q2 | 2026-06-30 | 无数据 | $489.2M | 85.3% | −152bp | −93bp | −88bp |
| 季度 | 截止日 | 合同负债 | CL g | RPO | RPO g | 账单额 | 账单额 g | RPO 覆盖 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $124.4M | −31.6% | 无数据 | 无数据 | $3.41B | +9.5% | 无数据 |
| 2026Q2 | 2026-06-30 | $157M | +6.9% |
| 季度 | 截止日 | OCF TTM | OCF g | CapEx TTM | CapEx g | FCF TTM | CapEx 密度 | SBC/FCF | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $3.69B | −0.6% | $492.3M | +29.3% | $3.2B | 3.8% | 20.9% | 5.2% |
| 2026Q2 | 2026-06-30 | $4.29B |
| 季度 | 截止日 | 存货 | 存货 g | 营收 g | 剪刀差 | DIO | DIO 同比 |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $2.25B | +38.0% | +11.8% | +26.2pp | 389.4 | +31.6 |
| 2026Q2 | 2026-06-30 | $1.77B | +17.7% | +12.5% | +5.3pp | 329.2 |
| 交易日 | 申报日 | 申报人 | 头衔 | 代码 | 股数 | 价格 | 金额 | 10b5-1 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-12 | 2026-11-16 | WAGNER CHARLES F JR | EVP, CO & FO | S | 15,286 | $547.87 | $8.37M |
口径:修正广度 =(近 30 日上调 − 下调)/(上调 + 下调),样本 < 3 不出;只展示衍生指标,不展示一致预期原值。 · 数据截至 2026-11-16 · 来源:Yahoo Finance / Nasdaq
未覆盖(期权覆盖为 S&P 500 期权持仓前 100 名每日、其余每周轮换)
口径:本股的警报事件历史(含基线);事件保留 90 天。
| 2026Q1 | 2026-03-31 | 无数据 | $392.8M | 86.8% | +146bp | −5bp | +2bp |
| 2025Q4 | 2025-12-31 | 无数据 | $466M | 85.4% | −112bp | −7bp | −75bp |
| 2025Q3 | 2025-09-30 | 无数据 | $414.8M | 86.5% | +26bp | +68bp | +37bp |
| 2025Q2 | 2025-06-30 | 无数据 | $407.5M | 86.3% | −64bp | +31bp | +68bp |
| 2025Q1 | 2025-03-31 | 无数据 | $363M | 86.9% | +144bp | −37bp | −45bp |
| 2024Q4 | 2024-12-31 | 无数据 | $423.4M | 85.5% | −38bp | +8bp | +141bp |
口径:GM = 毛利/营收;毛利缺失时用 营收−销货成本 推导;环比/同比为基点。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 无数据 |
| $3.27B |
| +13.5% |
| 无数据 |
| 2026Q1 | 2026-03-31 | $218.7M | −4.2% | 无数据 | 无数据 | $3.03B | +8.7% | 无数据 |
| 2025Q4 | 2025-12-31 | $171.8M | −16.9% | 无数据 | 无数据 | $3.18B | +9.7% | 无数据 |
| 2025Q3 | 2025-09-30 | $182M | −17.3% | 无数据 | 无数据 | $3.11B | +8.7% | 无数据 |
| 2025Q2 | 2025-06-30 | $146.9M | +14.5% | 无数据 | 无数据 | $2.88B | +15.4% | 无数据 |
| 2025Q1 | 2025-03-31 | $228.4M | −17.2% | 无数据 | 无数据 | $2.79B | −0.2% | 无数据 |
| 2024Q4 | 2024-12-31 | $206.8M | +21.4% | 无数据 | 无数据 | $2.9B | +14.5% | 无数据 |
口径:g = 同比;账单额 = 营收 + Δ合同负债(同口径);RPO 覆盖 = RPO / TTM 营收。跨口径(总额/仅流动)不比较。 合同负债口径: 总额 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +11.6% |
| $496.8M |
| +43.3% |
| $3.8B |
| 3.9% |
| 18.2% |
| 5.5% |
| 2026Q1 | 2026-03-31 | $4.24B | 无数据 | $530.3M | +96.4% | $3.71B | 4.3% | 18.5% | 5.6% |
| 2025Q4 | 2025-12-31 | $3.63B | 无数据 | $437.6M | +47.0% | $3.19B | 3.6% | 21.5% | 5.7% |
| 2025Q3 | 2025-09-30 | $3.72B | 无数据 | $380.8M | +44.7% | $3.34B | 3.2% | 20.9% | 5.9% |
| 2025Q2 | 2025-06-30 | $3.85B | 无数据 | $346.7M | +46.8% | $3.5B | 3.0% | 19.6% | 6.0% |
| 2025Q1 | 2025-03-31 | -$980.3M | −124.9% | $270M | +19.1% | -$1.25B | 2.4% | FCF≤0 | 6.1% |
| 2024Q4 | 2024-12-31 | -$492.6M | −113.9% | $297.7M | +48.6% | -$790.3M | 2.7% | FCF≤0 | 6.3% |
口径:TTM = 近四个离散单季之和;FCF = OCF − CapEx;CapEx 密度 = CapEx/营收 TTM;FCF≤0 时 SBC/FCF 不计算。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| −6.5 |
| 2026Q1 | 2026-03-31 | $1.77B | +29.9% | +7.8% | +22.1pp | 410.4 | +68.6 |
| 2025Q4 | 2025-12-31 | $1.69B | +39.9% | +9.5% | +30.4pp | 330.3 | +70.5 |
| 2025Q3 | 2025-09-30 | $1.63B | +50.7% | +11.0% | +39.7pp | 357.9 | +106.9 |
| 2025Q2 | 2025-06-30 | $1.5B | +63.9% | +12.1% | +51.9pp | 335.7 | +111.3 |
| 2025Q1 | 2025-03-31 | $1.36B | +67.2% | +3.0% | +64.3pp | 341.8 | +125.2 |
| 2024Q4 | 2024-12-31 | $1.21B | +63.2% | +15.7% | +47.5pp | 259.8 | +76.6 |
口径:剪刀差 = 存货同比 − 营收同比(pp,正值=存货增速快于营收);DIO = 存货/销货成本 × 91.25 天。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| ✓ |
| 2026-11-06 | 2026-11-10 | Kewalramani Reshma | CEO & President | S | 11,866 | $531.53 | $6.31M | ✓ |
| 2026-07-02 | 2026-07-07 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | S | 1,500 | $524.99 | $787.49K | ✓ |
| 2026-07-02 | 2026-07-07 | McKechnie Duncan | EVP, Chief Commercial Officer | S | 1,541 | $519.00 | $799.78K | ✓ |
| 2026-07-01 | 2026-07-06 | Liu Joy | EVP and Chief Legal Officer | S | 828 | $502.71 | $416.24K | ✓ |
| 2026-06-26 | 2026-06-30 | Bozic Carmen | EVP and CMO | S | 596 | $482.50 | $287.57K | ✓ |
| 2026-06-18 | 2026-06-23 | Bozic Carmen | EVP and CMO | S | 1,020 | $462.17 | $471.41K | ✓ |
| 2026-06-15 | 2026-06-17 | Bozic Carmen | EVP and CMO | S | 4,062 | $450.00 | $1.83M | ✓ |
| 2026-06-05 | 2026-06-09 | Bozic Carmen | EVP and CMO | S | 1,745 | $450.00 | $785.25K | ✓ |
| 2026-06-01 | 2026-06-03 | Liu Joy | EVP and Chief Legal Officer | S | 828 | $439.91 | $364.25K | ✓ |
| 2026-05-29 | 2026-06-02 | Bozic Carmen | EVP and CMO | S | 1,974 | $450.00 | $888.3K | ✓ |
| 2026-05-15 | 2026-05-19 | Bunnage Mark E. | EVP, Chief Scientific Officer | S | 33 | $453.45 | $14.96K | ✓ |
| 2026-05-15 | 2026-05-19 | Bozic Carmen | EVP and CMO | S | 1,354 | $453.45 | $613.97K | ✓ |
| 2026-05-12 | 2026-05-14 | Bozic Carmen | EVP and CMO | S | 6,988 | $450.00 | $3.14M | ✓ |
| 2026-05-04 | 2026-05-05 | Bhatia Sangeeta N. | — | S | 318 | $423.73 | $134.75K | ✓ |
| 2026-05-01 | 2026-05-05 | Liu Joy | EVP and Chief Legal Officer | S | 1,104 | $425.02 | $469.22K | ✓ |
| 2026-04-01 | 2026-04-03 | Liu Joy | EVP and Chief Legal Officer | S | 978 | $449.17 | $439.29K | ✓ |
| 2026-03-27 | 2026-03-31 | Bozic Carmen | EVP and CMO | S | 2,329 | $450.95 | $1.05M | ✓ |
| 2026-03-13 | 2026-03-17 | Bozic Carmen | EVP and CMO | S | 2,329 | $481.79 | $1.12M | ✓ |
| 2026-03-11 | 2026-03-13 | McKechnie Duncan | EVP, Chief Commercial Officer | S | 2,633 | $498.42 | $1.31M | ✓ |
| 2026-03-04 | 2026-03-06 | McKechnie Duncan | EVP, Chief Commercial Officer | S | 2,437 | $475.30 | $1.16M | ✓ |
| 2026-03-02 | 2026-03-04 | Liu Joy | EVP and Chief Legal Officer | S | 892 | $495.96 | $442.4K | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 15,580 | $495.38 | $7.72M | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 3,498 | $494.33 | $1.73M | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 2,520 | $493.29 | $1.24M | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 949 | $491.30 | $466.24K | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 2,725 | $490.54 | $1.34M | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 5,995 | $496.16 | $2.97M | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 1,725 | $496.95 | $857.24K | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 460 | $489.32 | $225.09K | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 400 | $479.75 | $191.9K | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 120 | $481.50 | $57.78K | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 240 | $482.84 | $115.88K | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 2,510 | $487.13 | $1.22M | ✓ |
| 2026-02-27 | 2026-03-03 | Kewalramani Reshma | CEO & President | S | 3,278 | $488.27 | $1.6M | ✓ |
| 2026-02-27 | 2026-03-03 | Bozic Carmen | EVP and CMO | S | 2,329 | $480.31 | $1.12M | ✓ |
| 2026-02-26 | 2026-03-02 | Ambrose Kristen | SVP & Chief Accounting Officer | S | 357 | $483.36 | $172.56K | ✓ |
| 2026-02-25 | 2026-02-26 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | S | 260 | $486.35 | $126.45K | ✓ |
| 2026-02-25 | 2026-02-26 | Sachdev Amit | EVP Chief Patient & Ext Af Off | S | 1,846 | $486.35 | $897.8K | ✓ |
| 2026-02-25 | 2026-02-26 | McKechnie Duncan | EVP, Chief Commercial Officer | S | 2,500 | $486.35 | $1.22M | ✓ |
口径:Form 4/4A 公开市场买入(P)与卖出(S),申报人为董事或高管;汇总与集群为近 365 天,明细为最近 40 笔。 · 数据截至 2026-11-16 · 来源:SEC EDGAR Form 4
口径:SI 来自 FINRA(双周结算);SI% 分母 = SEC 封面总股本;借券费为 IBKR 报价(非全市场);卖空占比 = 当日卖空量/总成交量。 · 数据截至 SI 2026-10-30 · Reg SHO 2026-11-16 · 借券 2026-11-11 · 沿用上一版 · 来源:FINRA、IBKR、iBorrowDesk